We are experiencing some temporary issues. The market data on this page is currently delayed. Please bear with us as we address this and restore your personalized lists.
Beam Therapeutics Inc. (BEAM)
Chart Events
Performance Outlook
| Previous Close | 30.76 |
| Open | 30.19 |
| Bid | 29.38 x 900 |
| Ask | 29.52 x 1000 |
| Day's Range | 28.54 - 30.32 |
| 52 Week Range | 16.95 - 51.60 |
| Volume | |
| Avg. Volume | 1,221,253 |
| Market Cap | 2.364B |
| Beta (5Y Monthly) | 1.59 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -4.17 |
| Earnings Date | Nov 08, 2023 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 53.69 |
Fair Value
Subscribe to Yahoo Finance Plus to view Fair Value for BEAM
Related Research
- Beam Therapeutics Inc.Analyst Report: Exact Sciences CorporationExact Sciences Corporation, headquartered in Madison, Wisconsin, provides cancer screening and diagnostic test products in the United States and internationally. Exact’s Cologuard screening test, a noninvasive stool-based DNA test, is a pre-cancer screening test for colorectal cancer. The company also competes in the precision oncology market with Oncotype DX, a suite of tissue-based genomic tests for estimating recurrence risk and likelihood of benefit from chemotherapy for breast and colon cancer, and OncoExTra, a liquid-based comprehensive genomic profiling test. It is developing liquid biopsy tests for molecular residual disease, colorectal cancer screening, and multicancer screening, too.RatingFair ValueEconomic Moat3 days agoMorningstar
Motley FoolIs Beam Therapeutics Stock a Buy Now?
When it comes to gene-editing companies on the cutting edge, Beam Therapeutics (NASDAQ: BEAM) is keen to be one of the leaders. While it's a bit of a laggard in terms of its pipeline's maturity compared to a few of its competitors, few would claim that its technology platform is unimpressive. Like most biotech stocks that haven't yet commercialized any medicines, Beam is living on borrowed time.
Motley Fool3 Monster Stocks in the Making
Here's why three Motley Fool contributors think Beam Therapeutics (NASDAQ: BEAM), CRISPR Therapeutics (NASDAQ: CRSP), and Sarepta Therapeutics (NASDAQ: SRPT) have what it takes. Keith Speights (Beam Therapeutics): Some technologies simply have the "it factor." Base editing is a type of gene editing.
ZacksWhat Makes Beam Therapeutics Inc. (BEAM) a New Buy Stock
Beam Therapeutics Inc. (BEAM) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Motley FoolRight Now Could Be a Once-in-a-Generation Opportunity to Buy These Cathie Wood Stocks
This is especially true, in my view, for the stocks of companies that focus on highly innovative technologies -- the kinds of stocks that Ark Invest tends to own. With that in mind, I believe that right now could be a once-in-a-generation opportunity to buy these three Cathie Wood stocks. Twilio's Customer Engagement Platform enables companies to communicate directly with customers via text, email, and voice.
ZacksDoes Beam Therapeutics Inc. (BEAM) Have the Potential to Rally 139.76% as Wall Street Analysts Expect?
The average of price targets set by Wall Street analysts indicates a potential upside of 139.8% in Beam Therapeutics Inc. (BEAM). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
ZacksBeam Therapeutics (BEAM) Q3 Earnings & Revenues Beat Estimates
Beam Therapeutics' (BEAM) third-quarter 2023 earnings and revenues surpass expectations. The company focuses on developing genome-editing candidate, BEAM-101.
GlobeNewswireBeam Therapeutics Reports Pipeline and Business Updates and Third Quarter 2023 Financial Results
Recent Portfolio Prioritization Focuses Business on Key Near-term Value Drivers and Long-term Growth of Precision Genetic Medicines Pipeline Lilly Acquires Beam’s Opt-In Rights to Verve Therapeutics’ Base Editing Cardiovascular Programs for up to $600 Million in Combined Upfront Payment, Equity Investment and Potential Future Development-Stage Payments GMP Operations Initiated at Beam's North Carolina Manufacturing Facility Strong Balance Sheet Provides Anticipated Operating Runway into the Seco
- GlobeNewswire
Beam Therapeutics to Participate in 2023 Jefferies London Healthcare Conference
CAMBRIDGE, Mass., Nov. 08, 2023 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced that John Evans, chief executive officer, plans to participate in a fireside chat during the 2023 Jefferies London Healthcare Conference on Wednesday, November 15, 2023 at 4:30 p.m. GMT in London. A live webcast will be available in the investor section of the company's website at www.beamtx.com, and will b
Investor's Business DailyCathie Wood's ARK Innovation Just Had Its Best Week Ever Thanks To Roku, These Huge Winners
Cathie Wood's flagship Ark Innovation ETF ARKK just had its best week ever thanks to Roku, DraftKings, Palantir and other huge winners on big news.
Motley Fool2 Magnificent Growth Stocks That Might Be Badly Mispriced Right Now
Biotech stocks are amid a multiyear slump. While it would be easy to lay the blame squarely on the Federal Reserve's dramatic rate hikes, that's not the whole story. In reality, many biotechs brought this situation upon themselves.
People Also Watch
| Symbol | Last Price | Change | % Change |
|---|---|---|---|
| NTLA Intellia Therapeutics, Inc. | |||
| EDIT Editas Medicine, Inc. | |||
| TWST Twist Bioscience Corporation | |||
| FATE Fate Therapeutics, Inc. | |||
| CRSP CRISPR Therapeutics AG |
Similar to BEAM
| Symbol | Last Price | Change | % Change |
|---|---|---|---|
| NTLA Intellia Therapeutics, Inc. | |||
| VERV Verve Therapeutics, Inc. | |||
| EDIT Editas Medicine, Inc. | |||
| CRSP CRISPR Therapeutics AG | |||
| VRTX Vertex Pharmaceuticals Incorporated |
Analyst Price Targets (13)
Upgrades & Downgrades
| Maintains | Cantor Fitzgerald: Overweight to Overweight | 10/17/2023 | |
| Reiterates | Cantor Fitzgerald: Overweight to Overweight | 9/13/2023 | |
| Reiterates | Cantor Fitzgerald: Overweight to Overweight | 8/29/2023 | |
| Maintains | Barclays: Equal-Weight to Equal-Weight | 8/9/2023 | |
| Maintains | Credit Suisse: Neutral to Neutral | 8/9/2023 | |
| Maintains | Citigroup: Buy to Buy | 8/9/2023 |
Company Profile
238 Main Street
9th Floor
Cambridge, MA 02142-1016
United States
857 327 8775
https://beamtx.com
Sector(s): Healthcare
Industry: Biotechnology
Full Time Employees: 439
Beam Therapeutics Inc., a biotechnology company, engages in the development of precision genetic medicines for patients suffering from serious diseases in the United States. It develops BEAM-101 and BEAM-102 for the treatment of sickle cell disease beta thalassemia; BEAM-201, an allogeneic chimeric antigen receptor T cell for the treatment of refractory T-cell acute lymphoblastic leukemia/T cell lymphoblastic lymphoma; BEAM-301, a liver-targeting LNP formulation for the treatment of glycogen storage disease 1a; and BEAM-302, a liver-targeting LNP formulation to treat severe alpha-1 antitrypsin deficiency. The company has research collaboration agreement with Pfizer Inc., focus on in vivo base editing programs for targets rare genetic diseases of the liver, muscle, and central nervous system; Apellis Pharmaceuticals to conduct preclinical research on target specific genes within the complement system in various organs, including the eye, liver, and brain; Verve Therapeutics, Inc., for cardiovascular disease treatments; Sana Biotechnology, Inc., to research, develop, and commercialize rights to CRISPR Cas12b for cell therapy programs; Orbital Therapeutics design RNA for the prevention, treatment or diagnosis of human disease; and the Institute of Molecular and Clinical Ophthalmology Basel for treatment of impaired vision and blindness. Beam Therapeutics Inc. was incorporated in 2017 and is based in Cambridge, Massachusetts.
